Respiratory Monitoring System Safety and Performance Study

April 2, 2023 updated by: RTM Vital Signs, LLC

The goal of this observational study is collect data to evaluate the efficacy of the RMS system in monitoring, recording, and presenting respiratory function data to the user in participants scheduled for pulmonary function testing (PFT).

Participants will complete:

  • 60 episodes of data collection with a decreased tidal volume
  • 30 episodes of data collection with an increased tidal volume
  • 80 episodes with normal tidal volume breathing

The TSS will continuously transmit sound data to an adjacent personal computer (PC) via Bluetooth Low-Energy (BLE). TSS trachea sound data will be recorded on the PC and then transmitted via a secure wireless network to an RTM cloud account that is HIPPA compliant.

Reference breathing data will be simultaneously recorded using an FDA approved hospital ventilator (Hamilton Medical, HAMILTON-C1) with a calibrated pneumotach, capnometer, and a tight-fitting face mask. This system accurately measures and records a spontaneously breathing patient's RR, TV, MV, and end-tidal carbon dioxide concentration.

Study Overview

Detailed Description

Observational single-center data will be captured on up to 50 patients scheduled for pulmonary function testing (PFT) at Thomas Jefferson University Hospital's (TJUH) outpatient PFT facility. Plan is to record a complete data set from 30 patients. Breathing data for this study will be collected in the PFT facility by research personnel approximately 1 hour before or after the scheduled PFT test. Study personnel will adhere the TSS to the skin over the proximal trachea (midline above the sternal notch). The patient's neck will be examined prior to TSS attachment.

The TSS will continuously transmit sound data to an adjacent personal computer (PC) via Bluetooth Low-Energy (BLE). TSS trachea sound data will be recorded on the PC and then transmitted via a secure TJUH wireless network to an RTM cloud account that is HIPPA compliant.

Reference breathing data will be simultaneously recorded using an FDA approved hospital ventilator (Hamilton Medical, HAMILTON-C1) with a calibrated pneumotach, capnometer, and a tight-fitting face mask. This FDA approved system accurately measures and records a spontaneously breathing patient's RR, TV, MV, and end-tidal carbon dioxide concentration.

Study subjects will breathe through the HAMILTON ventilator's face mask, , capnometer, and pneumotach over a range of RR, TV, and MV with the data recorded on a computer. Each study subject will breathe with a normal RR, TV, and MV for approximately 5 minutes. Each subject will then breathe with a normal RR and a decreased tidal volume for approximately 60 to 80 seconds episode (shallow breathing), followed by a rest period (normal breathing). Each subject will then breathe with a normal RR and an increased tidal volume for approximately 60 to 80 seconds episode (deep breathing), followed by a rest period (normal breathing). This series of breathing will take approximately 7.5 minutes to record. Each subject will complete a second series of breathing using the identical methods. Study subjects will observe a computer screen that displays breath- by-breath tidal volume to help them maintain their tidal volume in the desired range during each recording.

Plan is to record and analyze approximately 280 breaths per study subject and 8,400 breaths from the 30 study subjects.

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Recruiting
        • Thomas Jefferson University Hospital
        • Contact:
        • Principal Investigator:
          • Marc Torjman, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Approximately an equal number of male/female subjects will be studied. Approximately an equal number of subjects will be in the 21 to 40 age range, the 41 to 60 age range, and the > 60 age range. Outpatients scheduled for testing at the PFT Laboratory facility at Thomas Jefferson University Hospital will be recruited for study. Breathing data will be collected by study personnel approximately one hour before or after the scheduled PFT. All patients who meet required inclusion and exclusion criteria are eligible for enrollment.

Description

Inclusion Criteria:

  • Age 21 to ≤ 80 years
  • Subject has no active signs/symptoms of a respiratory infection, severe asthma, severe bronchitis, severe emphysema, or unstable cardiovascular disease at the time of data collection
  • Body Mass Index between 18 to 38
  • Subject willing and able to comply with the study procedures
  • Subject understands the English language, understands the risks, benefits, and alternatives to this research study, and is willing and able to give written informed consent

Exclusion Criteria:

  • Subject has an active respiratory infection, unstable cardiovascular disease, severe asthma, severe bronchitis, or severe emphysema at the time of study
  • Recent COVID illness (must be symptom free for > 10 days or recent COVID exposure within last 10 days
  • History of skin sensitivity to the sensor, adhesive, or face mask materials
  • Active inflammation or infection of the skin at the site of TSS attachment
  • Subject is pregnant or breastfeeding
  • Current participation in another industry sponsored drug or device study
  • Patient has a history of anxiety or claustrophobia related to wearing a face mask
  • Age < 21 or > 80 years old
  • BMI < 18 or > 38

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy of RMS of the RMS system in monitoring, recording, and presenting respiratory function data to the user
Time Frame: 20 minutes
The RMS measures respiratory rate, approximate/relative tidal volume, and approximate/relative minute ventilation when compared to measurements made with the HAMILTON ventilator pneumotach device
20 minutes
Mean Measurement Accuracy Error for Respiratory Rate
Time Frame: 20 minutes
Mean measurement accuracy error for RR across all subjects shall be ≤ 5 % (±1 breath/minute) compared to the pneumotach
20 minutes
Mean Measurement Accuracy Error for Tidal Volume
Time Frame: 20 minutes
Mean measurement accuracy error for TV across all subjects shall be ≤15% compared to the pneumotach
20 minutes
Mean measurement accuracy error for Minute Ventilation
Time Frame: 20 minutes
Mean measurement accuracy error for MV across all subjects shall be ≤15% compared to the pneumotach
20 minutes
Mean measurement bias for Respiratory Rate
Time Frame: 20 minutes
Mean measurement bias (RMS-pneumotach) for RR shall be < 2% (95% limits of agreement ±1.96 SD)
20 minutes
Mean measurement bias for Tidal Volume
Time Frame: 20 minutes
Mean measurement bias (RMS-pneumotach) for TV shall be < 5% (95% limits of agreement ±1.96 SD)
20 minutes
Mean measurement bias for Minute Ventilation
Time Frame: 20 minutes
Mean measurement bias (RMS-pneumotach) for MV shall be < 5% (95% limits of agreement ±1.96 SD)
20 minutes
Tidal volume trend
Time Frame: 20 minutes
Tidal volume trend > 0.95 (r² correlation to pneumotach)
20 minutes
Mean measurement accuracy error for number of seconds since last breath
Time Frame: 20 minutes
Mean measurement accuracy error for number of seconds since last breath across all subjects shall be ≤ 5 % (± 2 seconds) compared to the pneumotach
20 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marc Torjman, PhD, Thomas Jefferson University and Hospitals Department of Anesthesiology and Perioperative Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 24, 2023

Primary Completion (Anticipated)

December 9, 2023

Study Completion (Anticipated)

December 9, 2023

Study Registration Dates

First Submitted

April 2, 2023

First Submitted That Met QC Criteria

April 2, 2023

First Posted (Actual)

April 13, 2023

Study Record Updates

Last Update Posted (Actual)

April 13, 2023

Last Update Submitted That Met QC Criteria

April 2, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CP-001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Rate

3
Subscribe